Lifecore Biomedical Inc. (LFCR)
Company Description
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally.
It operates through Lifecore, Curation Foods, and Other segments.
The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.
It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products.
This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets.
The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels.
The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022.
Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.

Country | United States |
IPO Date | Feb 15, 1996 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 524 |
CEO | Paul Josephs |
Contact Details
Address: 3515 Lyman Boulevard Chaska, Minnesota United States | |
Website | https://www.lifecore.com |
Stock Details
Ticker Symbol | LFCR |
Exchange | NASDAQ |
Fiscal Year | June - May |
Reporting Currency | USD |
CIK Code | 0001005286 |
CUSIP Number | n/a |
ISIN Number | US5147661046 |
Employer ID | 94-3025618 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Paul Josephs | President, Chief Executive Officer & Director |
James G. Hall | Advisor |
Thomas Guldager | Senior Vice President of Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 16, 2025 | 8-K | Current Report |
Apr 16, 2025 | 4 | Filing |
Apr 16, 2025 | 3 | Filing |
Apr 10, 2025 | 8-K | Current Report |
Apr 03, 2025 | 10-Q | Quarterly Report |
Apr 03, 2025 | 8-K | Current Report |
Feb 27, 2025 | DEF 14A | Filing |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 05, 2025 | SCHEDULE 13G/A | [Amend] Filing |